Previous Article | Next Article ![]()
Molecular and Cellular Biology, February 2001, p. 865-874, Vol. 21, No. 3
Departments of Microbiology and
Immunology,1
Pediatrics,2 and Epidemiology
and Social Medicine,3 Marion Bessin Liver
Research Center and Albert Einstein Comprehensive Cancer Center,
Albert Einstein College of Medicine, Bronx, New York 10461
Received 20 September 2000/Returned for modification 24 October
2000/Accepted 7 November 2000
Mutations in the von Hippel-Lindau (VHL) gene are involved in the
family cancer syndrome for which it is named and the development of
sporadic renal cell cancer (RCC). Reintroduction of VHL into RCC cells
lacking functional VHL [VHL( Mutations of the von Hippel-Lindau
(VHL) gene are involved in the family cancer syndrome for which it is
named and the development of sporadic renal cancer and renal cystic
disease (for review, see reference 15). VHL has no
significant homology to previously identified proteins
(21). Insights into the biochemistry of VHL have come
predominantly from the identification of proteins that associate with
VHL products (9, 17, 19, 26, 29, 34). These include
elongins B and C (9, 12, 19, 37), cul-2 (26,
34), and Rbx1 (17), which are similar to components of a yeast E3 ubiquitin ligase complex (2, 16, 26, 34). A
current hypothesis for VHL activity is that it functions as an F-box
protein, directing specific substrates for ubiquitination. Indeed, VHL
has been shown to have in vitro ubiquitin ligase activity (13,
25) and to target HIF-1 Alterations of cell-extracellular matrix (ECM) interactions are
associated with renal cystic disease (for review, see references 4, 10, and 40). A role for VHL in the
synthesis and degradation of ECM has begun to emerge. VHL was found to
associate with intracellular fibronectin and was required for assembly
of extracellular fibronectin (29). VHL also controls
matrix degradation by regulating both matrix metalloproteinases 2 and 9 and their inhibitors (20), as well as the urokinase-type
plasminogen activator system (27).
Previous studies indicated that reintroduction of VHL into carcinoma
cells lacking functional VHL [VHL( In this report, we describe VHL function in the context of cell-cell
and cell-ECM interactions. These studies demonstrate that VHL-dependent
morphological and biochemical differentiation requires the
establishment of high-density cell-cell contact and, in combination
with cell-ECM interactions, results in VHL-dependent growth arrest.
Cell lines and culture.
The VHL( Growth of cells on Matrigel.
To prepare a thin layer of
Matrigel, 300 µl of liquefied Matrigel (Becton Dickinson, Bedford,
Mass.) was spread evenly in the wells of 12-well plates (Corning,
Corning, N.Y.) precooled on ice. The plates were then placed at 37°C
for 30 min to allow the Matrigel to solidify. Aliquots containing
7 × 104 cells were plated in Matrigel-coated 22-mm
wells. To inhibit surface integrin activity, ascites preparations of
monoclonal antibodies P4C10 and P4G9 (Life Technologies) against Double thymidine block.
To arrest cells at the
G1-S border in the cell cycle, a double thymidine block was
performed as previously described (14). Briefly, cells
maintained for 1 week at 50 to 70% confluency were cultured for
17 h in medium containing 2 mM thymidine, washed with
phosphate-buffered saline (PBS), and cultured for 9 h without thymidine. Thereafter, cells were incubated for an additional 17 h
in the presence of 2 mM thymidine. Cells were detached with trypsin and
counted. An aliquot of cells was taken for cell cycle analysis by a
fluorescence-activated cell sorter (FACS), as described below. Each
cell line was analyzed in triplicate for each growth condition.
Image analysis.
A Nikon Diaphot inverted microscope equipped
with an environmental chamber was used to photograph cells by using
10× (phase 1; numerical aperture, 0.30 planapo) and 4× (phase L;
numerical aperture, 0.13 planapo) objectives. For video capture, an NEC TI-23A charge-coupled device (CCD) camera digitized with a Scion LG-3
video board in a Power Macintosh running NIH-Image was used. For still
photography, a Nikon N6000 35 mm camera was used. To collect images by
using Nomarski optics, a Photometrics (Tucson, Ariz.) KAF 1400 12-bit
cooled CCD camera on an inverted Olympus IX70 microscope was used with
a 20× objective (numerical aperture, 0.40 planapo) and I.P. Lab
Spectrum software (Scanalytics, Fairfax, Va.). Images were deconvolved
with Power Hazebuster software (Vaytek, Fairfield, Iowa) on a Power
Macintosh. All images were captured at the Analytical Imaging Facility
at Albert Einstein College of Medicine.
Scanning electron microscopy.
Cells cultured at confluency
for 1 week were dislodged with trypsin and plated on glass-bottom wells
at high density. After 2 days of growth, the cells were washed twice
with PBS and were then immediately fixed in 2.5% glutaraldehyde in 0.1 M sodium cacodylate (pH 7.4). The cells were dehydrated through a
graded series of ethanol washes and were critical-point dried using
liquid carbon dioxide in a Samdri 790 Critical Point Drier (Tousimis Research Corp., Rockville, Md.). The cells were sputter coated with
gold-palladium in a Vacuum Desk-1 Sputter Coater (Denton Vacuum Inc.,
Cherry Hill, N.J.) and examined in a JSM6400 Scanning Electron
Microscope (JEOL, Peabody, Mass.) using an accelerating voltage of 10 kV.
Macroscopic colony morphology assay.
The 786-O cell line was
transfected with the VHLp24(MPR) construct in a 35-mm-diameter dish by
using Lipofectamine (Life Technologies), as recommended by the
manufacturer. Three days after transfection, one-tenth of the cells
were plated in a 10-cm-diameter dish and selected with 1.2 mg of G418
(Life Technologies)/ml for 1 month. A Foto/Eclipse image analysis
system (Fotodyne, Hartland, Wis.) was used for the video capture of the image.
Cell growth on collagen I and plastic for cell cycle
analysis.
To prepare collagen I-coated plates, rat tail collagen I
(Becton Dickinson) was diluted 1:2 and neutralized with 0.1 N NaOH, as
recommended by the manufacturer. Each 10-cm-diameter plate was coated
with 2.5 ml of collagen I solution and incubated at 37°C for 30 min
to allow the collagen I to gel. Cells were plated in triplicate, and
medium was replenished daily after cells reached confluency.
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.3.865-874.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
VHL Induces Renal Cell Differentiation and Growth Arrest through
Integration of Cell-Cell and Cell-Extracellular Matrix
Signaling
and
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
)] can suppress their growth in nude
mice, but not under standard tissue culture conditions. To
examine the hypothesis that the tumor suppressor function of VHL
requires signaling through contact with extracellular matrix (ECM), 786-O VHL(
) RCC cells and isogenic sublines stably expressing VHL gene products [VHL(+)] were grown on ECMs. Cell-cell and cell-ECM signalings were required to elicit VHL-dependent
differences in growth and differentiation. VHL(+) cells differentiated
into organized epithelial sheets, whereas VHL(
) cells
were branched and disorganized. VHL(+) cells grown to high density on
collagen I underwent growth arrest, whereas VHL(
)
cells continued to proliferate. Integrin levels were up-regulated in
VHL(
) cells, and cell adhesion was down-regulated in VHL(+)
cells during growth at high cell density. Hepatocyte nuclear factor
1
, a transcription factor and global activator of proximal
tubule-specific genes in the nephron, was markedly up-regulated in
VHL(+) cells grown at high cell density. These data indicate that
VHL can induce renal cell differentiation and mediate
growth arrest through integration of cell-cell and cell-ECM signals.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
, a hypoxia inducible transcription factor, for proteasomal degradation (7, 18, 28, 38). However, the exact biochemical function(s) of VHL that is disrupted in
VHL disease and which results in susceptibility to clear renal cell
cancer (RCC) remains elusive.
)] leads to growth suppression in
nude mice but not in cells grown under standard culture conditions
(11, 33, 37). In addition, VHL-deficient RCC cells
ectopically expressing VHL demonstrated morphological differentiation
and growth arrest when grown as multicellular tumor spheroids, but not
under standard culture conditions (23). These studies
suggest the importance of the extracellular milieu to elicit biological
functions of VHL.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
) cell lines consist of
the parental renal carcinoma cell line, 786-O, and its derivative lines
containing either the empty expression vector pCR3 (Invitrogen,
Carlsbad, Calif.) or a nonfunctional VHL deletion construct,
VHL(MPR)del(114-178) (37). The VHL(+) cell lines consist
of 786-O derivative lines stably expressing the VHLp24(MPR) or the
VHLp18(MEA) constructs as previously described (37).
At least two independent clones were analyzed for each construct. Cells
were grown in 10-cm-diameter dishes in a humidified incubator (37°C,
5% CO2) with Dulbecco's modified Eagle's medium (DMEM)
containing 10% fetal calf serum. Stable transfectants were maintained
in medium supplemented with 0.6 mg of G418 (Life Technology, Rockville,
Md.)/ml. Medium was replenished every 2 to 3 days. To condition cells
at high density, cells were allowed to grow for 1 week postconfluency
with media replenishment every 24 to 48 h. To condition cells at
low density, cells were maintained at 30 to 70% confluency for 1 week
by frequent passaging.
1
and
4 integrins, respectively, were diluted 1:50 in 1 ml of growth
media containing 106 suspended cells. Following a 1-h
incubation at room temperature, cells and diluted ascites fluid were
plated onto thin layers of Matrigel and incubated at 37°C.
Western blotting.
Cell lysates were prepared by washing
cells twice with PBS and lysing cells with 1 ml of 2× sodium dodecyl
sulfate loading buffer (100 mM Tris-HCl [pH 6.8], 200 mM
dithiothreitol, 4% sodium dodecyl sulfate, 20% glycerol) per 10-cm
plate. Lysates were heated for 10 min at 100°C, sonicated, and
assayed for protein concentration by the Bradford assay (Bio-Rad,
Hercules, Calif.). Monoclonal antibodies against leucine aminopeptidase
(B-F10; NeoMarkers, Union City, Calif.), hepatocyte nuclear factor 1
(HNF-1
),
5 integrin,
1 integrin
(Transduction Laboratories, San Diego, Calif.), and
3
integrin (P1B5) (Life Technologies Gibco BRL, Rockville, Md.) and
monoclonal antibody against VHL (11E12) (37) were
prepared, and those prchased commercially were used as recommended by
the manufacturers.
Analysis of surface expression of
1 integrin by
flow cytometry.
Cell lines were grown on plastic culture dishes
for 7 days at 30 to 70% confluence and for seven additional days after
attaining confluence. Cell lines were grown in triplicate, and each
plate was analyzed in triplicate. Cells were washed twice with PBS, suspended in PBS-0.1% EDTA, and blocked for 1 h in 1% fetal
calf serum in PBS. Samples containing 5 × 105 cells
from each cell line were incubated with 5 µl of TDM-29 antibody
labeled with phycoerythrin (Southern Biotechnology) for 1 h in 0.5 ml of blocking buffer, washed two times with blocking buffer, and fixed
in 1% paraformaldehyde (pH 7.5). All procedures from cell blocking
through cell fixation were performed at 4°C. A FACScan instrument
(Becton Dickinson Immunocytometry Systems) was used to perform the
analysis. Background values from negative controls (no
phycoerythrin-labeled antibody) were subtracted from the results of the
tested cell lines.
Adhesion assay.
Thin collagen I gels were applied to the
wells of a 96-well culture plate (Falcon, Franklin Lakes, N.J.) by
using 50 µl of a neutralized 2-mg/ml collagen I solution per well
(Becton Dickinson). VHL(+) and VHL(
) cell lines were maintained at
low density or at confluency for a week, suspended with trypsin-EDTA,
counted, plated at 5 × 104 cells per well in 100 µl
of growth medium, and incubated at 37°C for 30 min. Each line was
grown and analyzed in triplicate. The wells were washed three times
with growth medium and incubated with 1 mg of
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma)
per ml in DMEM (no serum) at 37°C for 1 h. The wells were washed
once with DMEM, and 100 µl of N-propanol (Fischer) was
added to dissolve the color indicator. The absorbance at 570 nm was
read on an MRX microplate reader (Dynatech Laboratories, Inc.,
Chantilly, Va.). Background values (wells with no cells) were
subtracted from the test values.
| |
RESULTS |
|---|
|
|
|---|
VHL and cell-cell signaling regulate cell morphology.
To test
the notion that cell-ECM interactions are necessary to elicit growth
control properties of VHL, the 786-O VHL(
) cell line and isogenic
derivatives expressing VHL constructs were grown on Matrigel, a
basement membrane preparation, to recapitulate growth conditions in
vivo. Two different phenotypes were observed within the first 20 h
of cell growth on Matrigel. Cells without functional VHL consistently
aligned, elongated, and spread to form a web-like pattern (Fig. 1A,
upper left). In
contrast, VHL(+) cells formed clusters of rounded cells (Fig. 1A, upper
right). Variability in the phenotype of the VHL(+) cells plated on
Matrigel was observed (Fig. 1A, right). To define the conditions
required to elicit the VHL(+) phenotype, the influence of cell-cell
contacts prior to growth on Matrigel was studied. Cells were maintained for 1 week at either low or high density and then were plated on
Matrigel. VHL(+) cells maintained at high density formed clusters on
Matrigel (Fig. 1A, upper right). However, cells maintained at low
density formed a web-like pattern similar to those formed by the
VHL(
) lines (Fig. 1A, lower right). These data indicated that the
VHL(+) phenotype was dependent on cell density prior to plating the
cells on Matrigel.
|
) cells. Cell cycle analysis by flow cytometry confirmed that the growth of thymidine-treated cells was inhibited (Fig. 1B) compared to the growth of the untreated cells. Nevertheless, cells grown at low density displayed a similar phenotype on Matrigel irrespective of thymidine treatment or VHL expression. Representative results are shown for the 786-O cell line stably expressing VHLp24(MPR) (Fig. 1B, untreated cells, middle panel; thymidine-treated cells, lower
panel). These results suggest that cell-cell contact and not cell cycle
differences are responsible for the VHL-mediated clustering of cells on Matrigel.
The necessity for high cell density to elicit a VHL-dependent phenotype
prompted studies on the roles of cell-cell contact and VHL expression
on cell growth in the absence of exogenous matrix. The morphologic
appearances and growth properties of VHL(
) and VHL(+) cells are
similar when maintained under standard culture conditions (9, 11,
37; data not shown). Scanning electron microscopy of cells grown
at high density revealed striking morphological differences that
paralleled the phenotypes observed on Matrigel (Fig.
2). VHL(
) cells growing above the
monolayer were elongated, scattered, and branched (Fig. 2A), whereas
VHL(+) cells growing above the monolayer were clustered and spherical
(Fig. 2B). Thus, growth at high cell density coupled with VHL
expression, in the absence of exogenous ECM, was sufficient to cause
significant VHL-dependent changes in cell morphology.
|
VHL and cell-cell signaling regulate the macroscopic organization
of cells.
The VHL-dependent morphologic alterations of cells at
high cell density suggested that multicellular organization might also be affected by VHL expression. To study the influence of VHL in the
morphogenesis of multicellular architecture, the development of VHL(+)
and VHL(
) colonies was observed during prolonged growth on plastic
culture dishes (Fig. 3). 786-O cells were
transfected with the VHLp24(MPR) expression construct and selected
for 4 weeks with G418 (Fig. 3A). Dramatic VHL-dependent differences in
colony morphology were observed. Two basic phenotypes developed and are exemplified by colonies 11 and 12 (Fig. 3B). Colonies similar to colony
11 had multiple clusters of cells growing above the monolayer, whereas
those similar to colony 12 had dense ridges of cells rising above the
monolayer, often forming spirals. To relate these phenotypes to VHL
expression, 12 colonies were selected for VHL immunoblot analysis (Fig.
3C). Colonies expressing high levels of VHLp24(MPR) protein
(colonies 2, 3, 5, 7, and 8) had morphologies similar to that of colony
11, whereas colonies expressing no VHLp24(MPR) protein (1, 4, and
9) had morphologies similar to that of colony 12. Colonies 6 and 10 expressed low levels of VHLp24(MPR) and displayed an intermediate
phenotype. Thus, the expression of VHL altered macroscopic colony
morphology during prolonged growth, and the magnitude of VHL expression
modulated the extent to which the morphology was modified.
|
VHL and cell-cell signaling regulate integrin levels and
activity.
In order to study possible mechanisms by which VHL and
cell density may influence cell morphology, integrin expression and cell adhesion were assayed. VHL(+) cells had reduced levels of
1,
3, and
5 integrins
compared to the levels of the VHL(
) cells when cells were grown for
10 additional days after attaining 100% confluence (Fig.
4A). The relationship
between cell density and integrin expression was further studied by
flow cytometry to determine the surface expression of
1
integrin (Fig. 4B) on subconfluent cells and cells grown for an
additional 7 days after attaining confluence. At high cell density,
surface
1 integrin levels increased in VHL(
) cells but
were unchanged in VHL(+) cells. Thus, VHL maintains surface levels of
1 integrin that would otherwise be up-regulated by
growth at high cell density.
|
) cells maintained under subconfluent conditions (Fig.
4C) were similarly adhesive to collagen I, consistent with their
phenotype on Matrigel (Fig. 1A, bottom). However, adhesion of VHL(+)
cells was markedly reduced for cells conditioned by growth for seven
additional days after attaining confluence (Fig. 4C), consistent with
their phenotype on Matrigel (Fig. 1A, right top). Moreover, cells
preconditioned at low density, which spread on Matrigel (Fig.
4D, top), were inhibited from spreading when treated with blocking
antibodies to
1 integrin (Fig. 4D, bottom), whereas
treatment with a control antibody had no effect (Fig. 4D, middle).
VHL(+) cell adhesion to collagen I and cell spreading on Matrigel were
highly dependent on cell density and were inhibited by blocking
antibodies to
1 integrin, whereas surface expression of
1 integrin on the VHL(+) cells was unaffected by cell
density, thus suggesting that
1 integrin-associated
activity is regulated by VHL.
VHL, cell-cell signaling, and cell-ECM signaling direct
morphological differentiation.
During prolonged growth on
Matrigel, VHL(
) and VHL(+) cells developed distinct patterns of
multicellular organization. After 5 to 7 days of growth on Matrigel,
both VHL(+) and VHL(
) cells contracted into large aggregates (Fig.
5A, left). The aggregates of VHL(
)
cells grew as dense spheres without an organized structure or
discernible cell morphology (Fig. 5A, upper left). In contrast, the
VHL(+) cells grew into organized structures characterized by a flat
round center surrounded by a raised outer rim in which cell boundaries
were clearly seen (Fig. 5A, lower left). By 12 days of growth on
Matrigel, cells began to grow out of the aggregates (Fig. 5A,
right). The VHL(
) cells were branched and disorganized (Fig. 5A,
upper right), whereas the VHL(+) cells were polygonal, were tightly
associated, and grew as a coherent epithelial sheet (Fig. 5A,
lower right). These results indicated that during growth for several
days with cell-cell contact, VHL expression was required for
Matrigel-cell signaling to direct the formation of organized structures
and an epithelial-like morphology.
|
) cells on collagen I was characterized by
branching and scattering of cells (Fig. 5B, upper left), whereas VHL(+)
cells grew in tight patches (Fig. 5B, lower left). At high cell
density, VHL(
) cells were disorganized, branched, and intercalated
(Fig. 5B, upper right), whereas VHL(+) cells formed a monolayer of
polygonal cells characteristic of differentiated epithelia (Fig. 5B,
lower right). Prior growth of VHL(+) cells at low density resulted in
their branching during the initial hours of growth on collagen I, but
they subsequently coalesced into tight patches of cobblestone-shaped
cells after 2 to 3 days of growth (data not shown), indicating that
cell density also plays a role in VHL-dependent morphological changes
on collagen I.
VHL, cell-cell signaling, and cell-ECM signaling direct growth
arrest.
VHL(+) cells maintained at high density for 4 weeks grew
out of the monolayer on tissue culture plastic (Fig. 3, colony 11), but
VHL(+) cells grown for 4 weeks on collagen I were confined to a
monolayer (data not shown). In contrast, VHL(
) cells grew out of the
monolayer both on plastic (Fig. 3, colony 12) and on collagen I (Fig.
5B, upper right) and invaded the collagen gel (data not shown).
) and VHL(+) cells. Strikingly, after 2 weeks of culture at high density, VHL(
) cells had higher percentages of S-phase cells on collagen I than on plastic (Fig. 6B),
whereas 2 weeks of culture at high density on collagen I led to the
growth arrest of VHL(+) cells (Fig. 6B, right) in the G0-G1 phase of the cell cycle (Fig. 6C).
|
) cells (data not shown). The relative expression
of these markers demonstrated that VHL(
) cells were proliferating on
collagen I while VHL(+) cells were growth arrested. These differences
were not seen when cells were grown on plastic. These data are
consistent with the observation that VHL(+) cells grow out of the
monolayer on plastic but are confined to a monolayer on collagen I
during prolonged growth.
VHL, cell-cell signaling, and cell-ECM signaling direct
biochemical differentiation.
The epithelial morphology of
VHL(+) cells, when cultured on ECM, suggested that VHL may also induce
proximal tubule-specific biochemical differentiation. Therefore, the
expression of HNF-1
, a transcription factor responsible for the
maturation and maintenance of proximal tubule function
(35), was examined by immunoblotting (Fig.
7, top row). At low cell density,
HNF-1
protein was barely detectable in all cell lines (Fig. 7, lanes
1 to 5). Growth of VHL(
) cells at high cell density resulted in low
levels of HNF-1
(Fig. 7, lanes 6 to 8). The combination of VHL
expression and high cell density resulted in a dramatic increase in
HNF-1
(Fig. 7, lanes 9 and 10). Thus, both VHL expression and
cell-cell signaling were required for maximal induction of
HNF-1
. Protein levels of leucine aminopeptidase, a proximal tubule
brush-border enzyme and transcriptional target of HNF-1
, were
also increased in a cell density- and VHL-dependent manner (Fig. 7,
middle row) consistent with the induction of differentiation by VHL.
|
| |
DISCUSSION |
|---|
|
|
|---|
In this report, we demonstrate that establishment of cell-cell and
cell-ECM contact is necessary to elicit the biological functions of VHL
critical for the control of renal cell growth and differentiation. Both
the expression of functional VHL and the preconditioning of cells at
high density were necessary to inhibit branching during the first hours
of growth on Matrigel and collagen I, suggesting that VHL mediated
cross talk between cell-cell and cell-ECM signaling pathways.
Pharmacological inhibition of the cell cycle did not affect this
phenotype. Moreover, although their cell cycle profiles were similar,
the morphologies of VHL(+) and VHL(
) cells growing above the
monolayer were significantly different after prolonged growth on
plastic, further supporting the independence of cell cycle effects and
VHL-dependent cell morphology. Previous studies also indicated that
cell density and not cell cycle influenced the subcellular localization
of VHL in transfected COS cells (22).
In the absence of exogenous matrix, growth of cells at high density was
sufficient to manifest striking VHL-dependent changes in cell growth
and morphology. Cells growing above the monolayer were most visibly
affected as determined by scanning electron microscopy. VHL(+) cells
were round and formed tight clusters, whereas VHL(
) cells were
branched and scattered. Growth of cells as colonies for a prolonged
time also revealed VHL-dependent macroscopic differences in
multicellular organization. Prolonged growth on Matrigel and
polymerized collagen I stimulated VHL(+) cells to grow as a coherent
epithelial monolayer, whereas VHL(
) cells were disorganized and
branched and grew above the monolayer and into the ECM substrates. We
further demonstrate that VHL-dependent growth arrest is a consequence
of the morphologic confinement of growth to a monolayer on ECM.
VHL has been reported to bind fibronectin (29), and VHL
expression has been shown to correlate with the deposition of assembled fibronectin. Based on these observations, VHL was suggested to be
involved in fibronectin assembly, and signaling from fibronectin may be
involved in generating a differentiated phenotype (24, 29). However, 786-O cells showed no differences in growth on a
fibronectin coating from growth on plastic (data not shown). Additionally, VHL(+) and VHL(
) cells grown on matrices deposited by
either VHL(+) or VHL(
) cells were morphologically equivalent (data
not shown). Thus, fibronectin deposition is not sufficient to elicit
growth regulation of 786-O cells.
VHL has been reported to inhibit hepatocyte growth factor (HGF)-induced
invasion and branching morphogenesis in renal carcinoma cells
(20), consistent with the observations reported here that VHL expression inhibits branching and invasion. However, under the
conditions used in our studies, VHL(
) cells branched and were
invasive in the absence of exogenous HGF, suggesting that VHL activity
is independent of HGF signaling. Accordingly, activating mutations of
the MET receptor (i.e., the receptor of the HGF ligand) are associated
with papillary renal carcinomas and not clear RCCs in which
inactivation of VHL is typical (36).
Growth at high cell density markedly diminished the ability of
VHL-expressing cells to adhere to collagen I, although their integrin
levels were unaffected by cell density. In the absence of VHL
expression, cell density had a minimal affect on the adhesion of cells
to collagen I although integrin levels were markedly increased. Thus,
VHL and cell-cell signaling may be involved in the modulation of
integrin function and may help account for some of the VHL-dependent
morphologic and growth differences. In support of this contention,
treatment of subconfluent cells with antibody to
1 integrin
inhibited their spreading on ECM and produced a phenotype similar to
that seen in VHL(+) cells grown at high density which have reduced
integrin levels.
Polycystin-1, the PKD1 gene product, has been reported to associate
with focal adhesion complexes and has been similarly proposed to
down-regulate integrin-mediated epithelial cell adhesion to collagen I
(41). Murine polycystic kidney epithelial cell lines have
also been shown to have increased
1 integrin-mediated
adhesion to collagen I (39). In addition, renal cysts and
tumors from VHL patients have elevated levels of
3 and
5 integrins compared to those of normal proximal tubule
cells (32). Moreover, immunohistological studies of ECM
components in clear-cell renal carcinomas demonstrated that
approximately 50% of the tumors had detectable levels of collagen I in
contrast to the absence of collagen I in the ECM of normal proximal
tubules (8). Taken together, these observations suggest
that up-regulation of integrin mediated adhesion to collagen I may be a
common defect contributing to the pathogenesis of VHL-associated renal
cysts and clear-cell renal cancer.
Growth as a monolayer on ECM and tight cell-cell association exhibited
by VHL(+) cells suggested that cadherin proteins may be affected by
VHL. Immunoblot analysis of cadherins indicated that 786-O VHL(
)
cells and VHL(+) cells expressed equivalent levels of N-cadherin which
were similarly localized to the cell membrane (data not shown). No E or
K cadherin expression was detected in any of the lines (data not
shown). Furthermore, analysis of Triton-soluble and -insoluble
fractions from confluent cells grown on collagen I demonstrated similar
levels of N-cadherin by immunoblotting, indicating that differences in
N-cadherin are not associated with VHL-dependent morphologic
differentiation. Thus, VHL may regulate other cadherins and/or
molecules involved in cell-cell association.
The present data indicate that VHL mediates both biochemical and
morphological differentiation of renal cells, extending the data
presented by Lieubeau-Teillet et al. (24). VHL expression and high cell density mediated the up-regulation of HNF-1
, a transcriptional activator required for the expression of genes required
for the maturation and maintenance of proximal tubules (42). Leucine aminopeptidase, a brush-border enzyme
specific for the proximal tubule within the nephron, is a target for
HNF-1
(30, 31). Leucine aminopeptidase expression was
associated with the expression of HNF-1
, supporting a model whereby
VHL affects the global differentiation of renal proximal tubule cells. VHL-dependent up-regulation of proximal tubule-specific markers is
biologically significant since loss of differentiation is a characteristic of renal cysts and renal cell carcinomas
(5) which are thought to arise from proximal renal tubular
epithelial cells. HNF-1
functions as a homodimer or as a heterodimer
with HNF-1
to activate the transcription of renal proximal
tubule-specific proteins (30). HNF-1
function is lost
in most RCCs (1, 6, 23). Loss of HNF-1
function has
been associated with abnormal nephron development and multicystic
dysplastic kidneys (3). HNF-1
is also involved in the
maintenance of differentiation in the liver and pancreas
(35). VHL disease often leads to the development of cysts
in the kidney, liver, and pancreas, strengthening the argument that VHL
loss resulting in decreases in HNF-1
levels contributes more
globally to the pathogenesis of cysts and loss of differentiation. VHL
in concert with cell-cell signaling is positioned to control proximal
tubule differentiation by the activation and repression of numerous
developmentally regulated genes by the modulation, in part, of HNF-1
levels and/or activity. However, inherited mutations in the HNF-1
gene in humans are not associated with the development of renal cysts
and RCC (1). Thus, although we demonstrate that HNF-1
expression and proximal tubule epithelial cell differentiation are
dependent on the expression of functional VHL, the tumor suppressor
function of VHL cannot be based solely on the regulation of HNF-1
expression. This supports accumulating evidence that VHL functions
through multiple pathways.
Taken together, these results suggest a model in which VHL functions to
redirect cell-cell and cell-ECM signaling from inducing proliferative
and disorganized growth to inducing differentiation and growth arrest.
In the absence of VHL expression, growth at high cell density caused
increased integrin expression, whereas VHL-expressing cells grown at
high density were less adhesive and more differentiated, as indicated
by higher levels of HNF-1
. Cell growth at high density on ECM was
stimulated in the absence of VHL, whereas VHL(+) cells were growth
arrested. Thus, VHL plays a major role in determining whether cells
undergo growth arrest and differentiation or continue to proliferate in
an undifferentiated state.
| |
ACKNOWLEDGMENTS |
|---|
We thank Jeffrey Segal, Peter Mundel and Prasad Devarajan for critical review of the manuscript. We also thank Michael Cammer, Leslie Gunther, and Frank Macaluso for their assistance with microscopy and image analysis and David Gebhard for assistance with FACS analysis. All microscopy was performed at the Analytical Imaging Facility of the Albert Einstein College of Medicine. DNA oligonucleotides were synthesized in the oligonucleotide facility of the Comprehensive Cancer Center of the Albert Einstein College of Medicine (partially supported by grant CA 13330). Monoclonal antibodies were produced at the Hybridoma Facility of the Cancer Center of the Albert Einstein College of Medicine.
This work was supported, in part, by a grant from the VHL Family Alliance. A.R.S. was supported by a National Institutes of Health training grant (CA 09060). E.J.D. was supported by a National Institutes of Health training grant (DK 07218).
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Ullmann Bldg. Rm. 515, Albert Einstein College of Medicine, 1300 Morris Park Ave., Bronx, NY 10461. Phone: (718) 430-3720. Fax: (718) 430-8975. E-mail: burk{at}aecom.yu.edu.
Present address: Derald H. Ruttenberg Cancer Center, Mount Sinai
School of Medicine, New York, NY 10029.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Anastasiadis, A. G., I. Lemm, A. Radzewitz, A. Lingott, T. Ebert, R. Ackermann, G. U. Ryffel, and W. A. Schulz. 1999. Loss of function of the tissue specific transcription factor HNF1 alpha in renal cell carcinoma and clinical prognosis. Anticancer Res. 19:2105-2110[Medline]. |
| 2. | Bai, C., P. Sen, K. Hofmann, L. Ma, M. Goebl, J. W. Harper, and S. J. Elledge. 1996. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 86:263-274[CrossRef][Medline]. |
| 3. | Bingham, C., S. Ellard, L. Allen, M. Bulman, M. Shepherd, T. Frayling, P. J. Berry, P. M. Clark, T. Linder, G. I. Bell, G. U. Ryffel, A. J. Nicholls, and A. T. Hattersley. 2000. Abnormal nephron development associated with a frameshift mutation in the transcription factor hepatocyte nuclear factor-1 beta. Kidney Int. 57:898-907[CrossRef][Medline]. |
| 4. | Calvet, J. P. 1998. Molecular genetics of polycystic kidney disease. J. Nephrol. 11:24-34[Medline]. |
| 5. | Calvet, J. P. 1993. Polycystic kidney disease: primary extracellular matrix abnormality or defective cellular differentiation? Kidney Int. 43:101-108[Medline]. |
| 6. |
Clairmont, A.,
T. Ebert,
H. Weber,
C. Zoidl,
P. Eickelmann,
W. A. Schulz,
H. Sies, and G. U. Ryffel.
1994.
Lowered amounts of the tissue-specific transcription factor LFB1 (HNF1) correlate with decreased levels of glutathione S-transferase alpha messenger RNA in human renal cell carcinoma.
Cancer Res.
54:1319-1323 |
| 7. |
Cockman, M. E.,
N. Masson,
D. R. Mole,
P. Jaakkola,
G. W. Chang,
S. C. Clifford,
E. R. Maher,
C. W. Pugh,
P. J. Ratcliffe, and P. H. Maxwell.
2000.
Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.
J. Biol. Chem.
275:25733-25741 |
| 8. | Droz, D., N. Patey, F. Paraf, Y. Chretien, and J. Gogusev. 1994. Composition of extracellular matrix and distribution of cell adhesion molecules in renal cell tumors. Lab. Investig. 71:710-718[Medline]. |
| 9. |
Duan, D. R.,
J. S. Humphrey,
D. Y. Chen,
Y. Weng,
J. Sukegawa,
S. Lee,
J. R. Gnarra,
W. M. Linehan, and R. D. Klausner.
1995.
Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations.
Proc. Natl. Acad. Sci. USA
92:6459-6463 |
| 10. |
Harris, P. C.
1999.
Autosomal dominant polycystic kidney disease: clues to pathogenesis.
Hum. Mol. Genet.
8:1861-1866 |
| 11. | Iliopoulos, O., A. Kibel, S. Gray, and W. G. Kaelin. 1995. Tumor suppression by the human von Hippel-Lindau gene product. Nat. Med. 1:822-826[CrossRef][Medline]. |
| 12. |
Iliopoulos, O.,
M. Ohh, and W. G. Kaelin, Jr.
1998.
pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation.
Proc. Natl. Acad. Sci. USA
95:11661-11666 |
| 13. |
Iwai, K.,
K. Yamanaka,
T. Kamura,
N. Minato,
R. C. Conaway,
J. W. Conaway,
R. D. Klausner, and A. Pause.
1999.
Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex.
Proc. Natl. Acad. Sci. USA
96:12436-12441 |
| 14. | Johnson, R. T., C. S. Downes, and R. E. Meyn. 1993. The synchronization of mammalian cells, p. 1-24. In P. Fantes, and R. Brooks (ed.), The cell cycle: a practical approach. IRL Press, Ltd., Oxford, United Kingdom. |
| 15. | Kaelin, W. G., Jr., and E. R. Maher. 1998. The VHL tumour-suppressor gene paradigm. Trends Genet. 14:423-426[CrossRef][Medline]. |
| 16. |
Kamura, T.,
M. N. Conrad,
Q. Yan,
R. C. Conaway, and J. W. Conaway.
1999.
The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2.
Genes Dev.
13:2928-2933 |
| 17. |
Kamura, T.,
D. M. Koepp,
M. N. Conrad,
D. Skowyra,
R. J. Moreland,
O. Iliopoulos,
W. S. Lane,
W. G. Kaelin, Jr.,
S. J. Elledge,
R. C. Conaway,
J. W. Harper, and J. W. Conaway.
1999.
Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase.
Science
284:657-661 |
| 18. |
Kamura, T.,
S. Sato,
K. Iwai,
M. Czyzyk-Krzeska,
R. C. Conaway, and J. W. Conaway.
2000.
Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex.
Proc. Natl. Acad. Sci. USA
97:10430-10435 |
| 19. |
Kibel, A.,
O. Iliopoulos,
J. A. DeCaprio, and W. G. Kaelin.
1995.
Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C.
Science
269:1444-1446 |
| 20. |
Koochekpour, S.,
M. Jeffers,
P. H. Wang,
C. Gong,
G. A. Taylor,
L. M. Roessler,
R. Stearman,
J. R. Vasselli,
W. G. Stetler-Stevenson,
W. G. Kaelin, Jr.,
W. M. Linehan,
R. D. Klausner,
J. R. Gnarra, and G. F. Vande Woude.
1999.
The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells.
Mol. Cell. Biol.
19:5902-5912 |
| 21. |
Latif, F.,
K. Tory,
J. Gnarra,
M. Yao,
F. M. Duh,
M. L. Orcutt,
T. Stackhouse,
I. Kuzmin,
W. Modi,
L. Geil,
L. Schmidt,
F. Zhou,
H. Li,
M. H. Wei,
F. Chen,
G. Glenn,
P. Choyke,
M. M. Walther,
Y. Weng,
D. R. Duan,
M. Dean,
D. Glavac,
F. Richards,
P. A. Crossey,
M. A. Ferguson-Smith,
D. L. Paslier,
I. Chumakov,
D. Cohen,
A. C. Chinault,
E. R. Maher,
W. M. Linehan,
B. Zbar, and M. I. Lerman.
1993.
Identification of the von Hippel-Lindau disease tumor suppressor gene.
Science
260:1317-1320 |
| 22. |
Lee, S.,
D. Y. T. Chen,
J. S. Humphrey,
J. R. Gnarra,
W. M. Linehan, and R. D. Klausner.
1996.
Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density.
Proc. Natl. Acad. Sci. USA
93:1770-1775 |
| 23. | Lemm, I., A. Lingott, E. Pogge v. Strandmann, C. Zoidl, M. P. Bulman, A. T. Hattersley, W. A. Schulz, T. Ebert, and G. U. Ryffel. 1999. Loss of HNF1alpha function in human renal cell carcinoma: frequent mutations in the VHL gene but not the HNF1alpha gene. Mol. Carcinog. 24:305-314[CrossRef][Medline]. |
| 24. |
Lieubeau-Teillet, B.,
J. Rak,
S. Jothy,
O. Iliopoulos,
W. Kaelin, and R. S. Kerbel.
1998.
von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids.
Cancer Res.
58:4957-4962 |
| 25. |
Lisztwan, J.,
G. Imbert,
C. Wirbelauer,
M. Gstaiger, and W. Krek.
1999.
The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity.
Genes Dev.
13:1822-1833 |
| 26. |
Lonergan, K. M.,
O. Iliopoulos,
M. Ohh,
T. Kamura,
R. C. Conaway,
J. W. Conaway, and W. G. Kaelin, Jr.
1998.
Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2.
Mol. Cell. Biol.
18:732-741 |
| 27. |
Los, M.,
S. Zeamari,
J. A. Foekens,
M. F. Gebbink, and E. E. Voest.
1999.
Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene.
Cancer Res.
59:4440-4445 |
| 28. | Ohh, M., C. W. Park, M. Ivan, M. A. Hoffman, T. Y. Kim, L. E. Huang, N. Pavletich, V. Chau, and W. G. Kaelin. 2000. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell. Biol. 2:423-427[CrossRef][Medline]. |
| 29. | Ohh, M., R. L. Yauch, K. M. Lonergan, J. M. Whaley, A. O. Stemmer-Rachamimov, D. N. Louis, B. J. Gavin, N. Kley, W. G. Kaelin, Jr., and O. Iliopoulos. 1998. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell 1:959-968[CrossRef][Medline]. |
| 30. |
Olsen, J.,
L. Laustsen,
U. Karnstrom,
H. Sjostrom, and O. Noren.
1991.
Tissue-specific interactions between nuclear proteins and the aminopeptidase N promoter.
J. Biol. Chem.
266:18089-18096 |
| 31. | Olsen, J., L. Laustsen, and J. Troelsen. 1994. HNF1 alpha activates the aminopeptidase N promoter in intestinal (Caco-2) cells. FEBS Lett. 342:325-328[CrossRef][Medline]. |
| 32. | Paraf, F., D. Chauveau, Y. Chretien, S. Richard, J. P. Grunfeld, and D. Droz. 2000. Renal lesions in von Hippel-Lindau disease: immunohistochemical expression of nephron differentiation molecules, adhesion molecules and apoptosis proteins. Histopathology 36:457-465[CrossRef][Medline]. |
| 33. |
Pause, A.,
S. Lee,
K. M. Lonergan, and R. D. Klausner.
1998.
The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal.
Proc. Natl. Acad. Sci. USA
95:993-998 |
| 34. |
Pause, A.,
S. Lee,
R. A. Worrell,
D. Y. Chen,
W. H. Burgess,
W. M. Linehan, and R. D. Klausner.
1997.
The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins.
Proc. Natl. Acad. Sci. USA
94:2156-2161 |
| 35. | Pontoglio, M., J. Barra, M. Hadchouel, A. Doyen, C. Kress, J. P. Bach, C. Babinet, and M. Yaniv. 1996. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell 84:575-585[CrossRef][Medline]. |
| 36. | Schmidt, L., F. M. Duh, F. Chen, T. Kishida, G. Glenn, P. Choyke, S. W. Scherer, Z. Zhuang, I. Lubensky, M. Dean, R. Allikmets, A. Chidambaram, U. R. Bergerheim, J. T. Feltis, C. Casadevall, A. Zamarron, M. Bernues, S. Richard, C. J. Lips, M. M. Walther, L. C. Tsui, L. Geil, M. L. Orcutt, T. Stackhouse, B. Zbar, et al. 1997. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 16:68-73[CrossRef][Medline]. |
| 37. |
Schoenfeld, A.,
E. J. Davidowitz, and R. D. Burk.
1998.
A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor.
Proc. Natl. Acad. Sci. USA
95:8817-8822 |
| 38. | Tanimoto, K., Y. Makino, T. Pereira, and L. Poellinger. 2000. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von hippel-lindau tumor suppressor protein. EMBO J. 19:4298-4309[CrossRef][Medline]. |
| 39. |
van Adelsberg, J.
1994.
Murine polycystic kidney epithelial cell lines have increased integrin-mediated adhesion to collagen.
Am. J. Physiol.
267:F1082-F1093 |
| 40. | Watnick, T., and G. G. Germino. 1999. Molecular basis of autosomal dominant polycystic kidney disease. Semin. Nephrol. 19:327-343[Medline]. |
| 41. | Wilson, P. D., and C. R. Burrow. 1999. Cystic diseases of the kidney: role of adhesion molecules in normal and abnormal tubulogenesis. Exp. Nephrol. 7:114-124[CrossRef][Medline]. |
| 42. | Witzgall, R. 1999. The proximal tubule phenotype and its disruption in acute renal failure and polycystic kidney disease. Exp. Nephrol. 7:15-19[CrossRef][Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2010 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»